Literature DB >> 10805483

Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort.

M Petri1.   

Abstract

Coronary artery disease (CAD) is a major cause of morbidity and mortality in SLE, including the Hopkins Lupus Cohort. Currently, 9% of the cohort have had clinical evidence (angina or myocardial infarction) of CAD. In our initial prospective study we found that duration of prednisone, hypertension, hyperlipidemia and obesity were risk factors for later CAD. We can now extend that list to include age, male sex, elevated homocysteine, renal insufficiency and antiphospholipid antibodies. Many of the risk factors are amenable to intervention, but the timing of intervention, and the effectiveness of intervention, must be determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805483     DOI: 10.1191/096120300678828226

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  62 in total

1.  Fatigue in systemic lupus erythematosus.

Authors:  Grace E Ahn; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2012-04-01

Review 2.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 3.  Can estrogens promote hypertension during systemic lupus erythematosus?

Authors:  Marcia Venegas-Pont; Michael J Ryan
Journal:  Steroids       Date:  2010-02-21       Impact factor: 2.668

4.  Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies.

Authors:  Sara Kashef; Mohammad Mehdi Ghaedian; Akbar Rajaee; Abbas Ghaderi
Journal:  Rheumatol Int       Date:  2006-08-30       Impact factor: 2.631

5.  Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study.

Authors:  C Christodoulou; M Zain; M L Bertolaccini; S Sangle; M A Khamashta; G R V Hughes; D P D'Cruz
Journal:  Ann Rheum Dis       Date:  2006-05       Impact factor: 19.103

6.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

7.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 8.  The role of preventive cardiology in systemic lupus erythematosus.

Authors:  Jennifer Rae Elliott; Susan Manzi; Daniel Edmundowicz
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

9.  Association of estimated sodium and potassium intake with blood pressure in patients with systemic lupus erythematosus.

Authors:  A Barnado; A Oeser; Y Zhang; C R Okafor; J Titze; C M Stein; C P Chung
Journal:  Lupus       Date:  2016-07-11       Impact factor: 2.911

10.  [Oxidatively modified lipoproteins and their antibodies in patients with antiphospholipid syndromeand systemic lupus erythematosus].

Authors:  B Roch; S Kopprasch; J Pietzsch; H-E Schröder
Journal:  Z Rheumatol       Date:  2004-08       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.